HOME >> BIOLOGY >> NEWS
Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM

San Diego, CA, September 27, 1998 - Clinical investigators today presented Phase III clinical trial data for the HIV protease inhibitor Agenerase` (amprenavir) which suggest that the drug may be potent and generally well-tolerated in combination with Epivir" (lamivudine) also known as 3TC", and Retrovir" (zidovudine; AZT). These data, presented at a late-breaker slide session at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) support the role of Agenerase in front-line combination antiretroviral therapy.

An as-treated analysis of interim 16 week data showed that 88% of patients taking triple therapy with Agenerase+Epivir+Retrovir achieved viral load below the limit of detection of standard assays (<400 copies/mL), compared to 19% of patients taking Epivir+Retrovir alone. An additional analysis showed that 59% of patients receiving this regimen achieved viral load below the limit of detection of an investigational ultrasensitive assay1 (<50 copies). An as-treated analysis evaluates only those patients who remain on study medication through the entire study period.

"In this trial, Agenerase appears to provide a significant amount of virus suppression when given in combination with two reverse transcriptase inhibitors," said Dr. Jeffrey Goodgame, M.D., lead investigator for the study and Associate Professor at the University of Central Florida. "Data generated in smaller studies have supported the potential clinical utility of Agenerase in a number of different regimens, including dual protease inhibitor combinations."

Agenerase (formerly known as 141W94 or VX-478) is a second-generation protease inhibitor that is now being made available in the United States to certain patients through an early access program. Phase III data presented today are intended to support applications to be submitted later in the fall by Vertex's partner Glaxo Wellcome for approval to market Agenerase in the United States and the European
'"/>

Contact: Michael Partridge
partridge@vpharm.com
(617) 577-6108
Vertex Pharmaceuticals
27-Sep-1998


Page: 1 2 3 4 5

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. OneWorld Health completes enrollment, treatment in Phase III India trial
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. KEPPRA international Phase IV SKATE study results show favourable efficacy
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
11. Phase transition in bilayers could affect their performance

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2019)... , ... February 21, 2019 , ... Clean label food ... expected when creating natural foods and beverages. It is quite common to spot consumers ... Yet, meat products are not immune to this label scrutiny. , More than ...
(Date:2/19/2019)... ... February 20, 2019 , ... ... that will see Dimensions rolled out across the organization. Dimensions provides in-depth ... across their business, support strategic planning, and understand past and future funding ...
(Date:2/14/2019)... ... February 14, 2019 , ... This year’s conference in ... 80 scientific sessions and 2,100 presentations. Given SOT’s mission to bring together researchers ... OpenLiver™ 3D cell culture model initiative that it recently launched with Biopredic ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading ... free, so be sure to register today to save your place! Participate in the ... our upcoming webinars, or click below to learn more about each webinar: , CLINICAL ...
(Date:1/30/2019)... ... January 29, 2019 , ... Could a computer detect a ... tricky math problem on an online tutoring program? Could it detect deep reflection ... science assistant professor Erin Solovey is working to develop a system ...
(Date:1/24/2019)... ... ... Controlled Contamination Services is pleased to announce three exciting new additions to ... team members will support its growing operation across the US and will be a ... This addition will enable CCS to widen its reach and provide enterprise wide solutions ...
(Date:1/20/2019)... ... January 16, 2019 , ... On January 15 of ... news article by Asymmetrex director James L. Sherley, M.D., Ph.D. The ... resources like the PGCB and CellTrials.org. Now in its 21st year of operation, ...
Breaking Biology Technology:
Cached News: